** Shares of Telix Pharmaceuticals TLX.AX fall 6% to A$26.86, their lowest since April 14
** Stock among the biggest percentage losers in the benchmark ASX200 index .AXJO
** Biotech firm says that the U.S. Food and Drug Administration (FDA) has refused to approve its new drug application for Pixclara, an investigational agent for imaging glioma
** FDA has requested additional clinical evidence to progress the application, stating that the application cannot be approved in its current form - TLX
** Stock fell as much as 9.3% earlier in the day, marking its worst intraday drop since April 7
** Stock up 9.7% YTD
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk http://www.x.com/thatstanishk;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.